ASX - By Stock
|
PER |
Re:
For General Information
|
|
Bellas
|
3.5K |
1.0M |
30 |
15/12/22 |
15/12/22 |
ASX - By Stock
|
3.5K
|
1.0M
|
30
|
|
ASX - By Stock
|
PER |
Re:
Ann: AGM Presentation
|
|
Bellas
|
60 |
22K |
4 |
17/11/22 |
17/11/22 |
ASX - By Stock
|
60
|
22K
|
4
|
|
ASX - By Stock
|
PER |
Re:
Pfizer & Sarepta investigate GT adverse events
|
|
Bellas
|
9 |
3.2K |
7 |
20/05/22 |
20/05/22 |
ASX - By Stock
|
9
|
3.2K
|
7
|
|
ASX - By Stock
|
IPL |
Re:
Unusual Omission re Calculation of Waggaman Lost Profit
|
|
Bellas
|
12 |
3.5K |
3 |
11/05/22 |
11/05/22 |
ASX - By Stock
|
12
|
3.5K
|
3
|
|
ASX - By Stock
|
IPL |
Re:
Unusual Omission re Calculation of Waggaman Lost Profit
|
|
Bellas
|
12 |
3.5K |
1 |
11/05/22 |
11/05/22 |
ASX - By Stock
|
12
|
3.5K
|
1
|
|
ASX - By Stock
|
IPL |
Re:
Unusual Omission re Calculation of Waggaman Lost Profit
|
|
Bellas
|
12 |
3.5K |
0 |
09/05/22 |
09/05/22 |
ASX - By Stock
|
12
|
3.5K
|
0
|
|
ASX - By Stock
|
IPL |
Re:
Unusual Omission re Calculation of Waggaman Lost Profit
|
|
Bellas
|
12 |
3.5K |
1 |
09/05/22 |
09/05/22 |
ASX - By Stock
|
12
|
3.5K
|
1
|
|
ASX - By Stock
|
IPL |
Re:
Unusual Omission re Calculation of Waggaman Lost Profit
|
|
Bellas
|
12 |
3.5K |
2 |
04/05/22 |
04/05/22 |
ASX - By Stock
|
12
|
3.5K
|
2
|
|
ASX - By Stock
|
IPL |
Re:
Unusual Omission re Calculation of Waggaman Lost Profit
|
|
Bellas
|
12 |
3.5K |
1 |
04/05/22 |
04/05/22 |
ASX - By Stock
|
12
|
3.5K
|
1
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
Bellas
|
3.5K |
1.0M |
2 |
02/05/22 |
02/05/22 |
ASX - By Stock
|
3.5K
|
1.0M
|
2
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
Bellas
|
3.5K |
1.0M |
9 |
01/05/22 |
01/05/22 |
ASX - By Stock
|
3.5K
|
1.0M
|
9
|
|
ASX - By Stock
|
IPL |
Unusual Omission re Calculation of Waggaman Lost Profit
|
|
Bellas
|
12 |
3.5K |
2 |
29/04/22 |
29/04/22 |
ASX - By Stock
|
12
|
3.5K
|
2
|
|
ASX - By Stock
|
IPL |
Re:
News: IPL Incitec Pivot Says Production At Waggaman Ammonia Plant Recommenced
|
|
Bellas
|
1 |
650 |
1 |
28/04/22 |
28/04/22 |
ASX - By Stock
|
1
|
650
|
1
|
|
ASX - By Stock
|
PER |
Re:
$15m cap raise Fresh Equities at 24c
|
|
Bellas
|
855 |
234K |
10 |
18/11/21 |
18/11/21 |
ASX - By Stock
|
855
|
234K
|
10
|
|
ASX - By Stock
|
PER |
Re:
$15m cap raise Fresh Equities at 24c
|
|
Bellas
|
855 |
234K |
11 |
04/11/21 |
04/11/21 |
ASX - By Stock
|
855
|
234K
|
11
|
|
ASX - By Stock
|
PER |
Re:
$15m cap raise Fresh Equities at 24c
|
|
Bellas
|
855 |
234K |
16 |
04/11/21 |
04/11/21 |
ASX - By Stock
|
855
|
234K
|
16
|
|
ASX - By Stock
|
PER |
Re:
$15m cap raise Fresh Equities at 24c
|
|
Bellas
|
855 |
234K |
7 |
29/10/21 |
29/10/21 |
ASX - By Stock
|
855
|
234K
|
7
|
|
ASX - By Stock
|
PER |
Re:
$15m cap raise Fresh Equities at 24c
|
|
Bellas
|
855 |
234K |
0 |
29/10/21 |
29/10/21 |
ASX - By Stock
|
855
|
234K
|
0
|
|
ASX - By Stock
|
PER |
Re:
$15m cap raise Fresh Equities at 24c
|
|
Bellas
|
855 |
234K |
4 |
29/10/21 |
29/10/21 |
ASX - By Stock
|
855
|
234K
|
4
|
|
ASX - By Stock
|
PER |
Re:
$15m cap raise Fresh Equities at 24c
|
|
Bellas
|
855 |
234K |
16 |
29/10/21 |
29/10/21 |
ASX - By Stock
|
855
|
234K
|
16
|
|
Charts
|
PER |
Re:
Chart
|
|
Bellas
|
5.9K |
2.2M |
23 |
27/10/21 |
27/10/21 |
Charts
|
5.9K
|
2.2M
|
23
|
|
ASX - By Stock
|
WHC |
Re:
Target $4.61
|
|
Bellas
|
6.8K |
2.2M |
7 |
20/10/21 |
20/10/21 |
ASX - By Stock
|
6.8K
|
2.2M
|
7
|
|
ASX - By Stock
|
PER |
Re:
Ann: Positive feedback received on Paediatric Investigation Plan
|
|
Bellas
|
221 |
79K |
10 |
30/09/21 |
30/09/21 |
ASX - By Stock
|
221
|
79K
|
10
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP Updates on US Regulatory Plans for ATL1102 in DMD
|
|
Bellas
|
174 |
46K |
5 |
13/08/21 |
13/08/21 |
ASX - By Stock
|
174
|
46K
|
5
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP Updates on US Regulatory Plans for ATL1102 in DMD
|
|
Bellas
|
174 |
46K |
11 |
12/08/21 |
12/08/21 |
ASX - By Stock
|
174
|
46K
|
11
|
|
ASX - By Stock
|
PER |
Re:
Ann: US FDA Feedback on Type C Meeting for ATL1102 in the US
|
|
Bellas
|
191 |
58K |
11 |
08/06/21 |
08/06/21 |
ASX - By Stock
|
191
|
58K
|
11
|
|
ASX - By Stock
|
PER |
Re:
Ann: US FDA Feedback on Type C Meeting for ATL1102 in the US
|
|
Bellas
|
191 |
58K |
21 |
08/06/21 |
08/06/21 |
ASX - By Stock
|
191
|
58K
|
21
|
|
ASX - By Stock
|
PER |
Re:
ANP presenting now
|
|
Bellas
|
183 |
76K |
25 |
14/05/21 |
14/05/21 |
ASX - By Stock
|
183
|
76K
|
25
|
|
ASX - By Stock
|
PER |
Re:
ANP presenting now
|
|
Bellas
|
183 |
76K |
11 |
29/04/21 |
29/04/21 |
ASX - By Stock
|
183
|
76K
|
11
|
|
ASX - By Stock
|
PER |
Re:
US deal for ATL1102
|
|
Bellas
|
202 |
74K |
16 |
22/04/21 |
22/04/21 |
ASX - By Stock
|
202
|
74K
|
16
|
|
ASX - By Stock
|
PER |
Re:
Sarepta gene therapy study missed key target in Duchennes
|
|
Bellas
|
413 |
164K |
5 |
23/03/21 |
23/03/21 |
ASX - By Stock
|
413
|
164K
|
5
|
|
ASX - By Stock
|
PER |
Re:
Sarepta gene therapy study missed key target in Duchennes
|
|
Bellas
|
413 |
164K |
17 |
21/03/21 |
21/03/21 |
ASX - By Stock
|
413
|
164K
|
17
|
|
ASX - By Stock
|
PER |
Re:
Sarepta gene therapy study missed key target in Duchennes
|
|
Bellas
|
413 |
164K |
25 |
18/02/21 |
18/02/21 |
ASX - By Stock
|
413
|
164K
|
25
|
|
Charts
|
PER |
Re:
Chart
|
|
Bellas
|
5.9K |
2.2M |
4 |
05/02/21 |
05/02/21 |
Charts
|
5.9K
|
2.2M
|
4
|
|
ASX - By Stock
|
PER |
Re:
Sarepta gene therapy study missed key target in Duchennes
|
|
Bellas
|
413 |
164K |
20 |
08/01/21 |
08/01/21 |
ASX - By Stock
|
413
|
164K
|
20
|
|
ASX - By Stock
|
PER |
Re:
Ann: 2020 Annual General Meeting Presentation
|
|
Bellas
|
72 |
24K |
0 |
25/12/20 |
25/12/20 |
ASX - By Stock
|
72
|
24K
|
0
|
|
ASX - By Stock
|
PER |
Re:
Ann: Receipt of R&D Tax Incentive payment
|
|
Bellas
|
65 |
18K |
9 |
09/12/20 |
09/12/20 |
ASX - By Stock
|
65
|
18K
|
9
|
|
ASX - By Stock
|
PER |
Re:
One Study Away
|
|
Bellas
|
35 |
9.0K |
9 |
19/11/20 |
19/11/20 |
ASX - By Stock
|
35
|
9.0K
|
9
|
|
ASX - By Stock
|
PER |
Re:
Ann: Pause in Trading
|
|
Bellas
|
97 |
24K |
8 |
26/10/20 |
26/10/20 |
ASX - By Stock
|
97
|
24K
|
8
|
|
ASX - By Stock
|
PER |
Re:
Ann: Quarterly Update and Appendix 4C
|
|
Bellas
|
8 |
2.4K |
3 |
21/10/20 |
21/10/20 |
ASX - By Stock
|
8
|
2.4K
|
3
|
|
Charts
|
PER |
Re:
Chart
|
|
Bellas
|
5.9K |
2.2M |
8 |
25/09/20 |
25/09/20 |
Charts
|
5.9K
|
2.2M
|
8
|
|
Charts
|
PER |
Re:
Chart
|
|
Bellas
|
5.9K |
2.2M |
7 |
24/09/20 |
24/09/20 |
Charts
|
5.9K
|
2.2M
|
7
|
|
Charts
|
PER |
Re:
Chart
|
|
Bellas
|
5.9K |
2.2M |
13 |
23/09/20 |
23/09/20 |
Charts
|
5.9K
|
2.2M
|
13
|
|
ASX - By Stock
|
PER |
Re:
Ionis Buys Akcea for $500 Million US (Implied Valuation of $2.1 Billion)
|
|
Bellas
|
13 |
4.7K |
3 |
05/09/20 |
05/09/20 |
ASX - By Stock
|
13
|
4.7K
|
3
|
|
ASX - By Stock
|
PER |
Re:
Ionis Buys Akcea for $500 Million US (Implied Valuation of $2.1 Billion)
|
|
Bellas
|
13 |
4.7K |
13 |
05/09/20 |
05/09/20 |
ASX - By Stock
|
13
|
4.7K
|
13
|
|
ASX - By Stock
|
PER |
Re:
The Blueprint Revisited
|
|
Bellas
|
26 |
6.8K |
12 |
26/08/20 |
26/08/20 |
ASX - By Stock
|
26
|
6.8K
|
12
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP Submits US Orphan Drug application for ATL1102 in DMD
|
|
Bellas
|
60 |
21K |
3 |
24/08/20 |
24/08/20 |
ASX - By Stock
|
60
|
21K
|
3
|
|
ASX - By Stock
|
PER |
Re:
Ann: ANP Submits US Orphan Drug application for ATL1102 in DMD
|
|
Bellas
|
60 |
21K |
4 |
24/08/20 |
24/08/20 |
ASX - By Stock
|
60
|
21K
|
4
|
|
ASX - By Stock
|
PER |
Re:
An FDA Act that may be relvant to ATL-1102 FDA
|
|
Bellas
|
210 |
60K |
16 |
15/08/20 |
15/08/20 |
ASX - By Stock
|
210
|
60K
|
16
|
|
ASX - By Stock
|
PER |
Re:
An FDA Act that may be relvant to ATL-1102 FDA
|
|
Bellas
|
210 |
60K |
22 |
13/08/20 |
13/08/20 |
ASX - By Stock
|
210
|
60K
|
22
|
|